Chase Investment Counsel Corp Has $207,000 Position in Johnson & Johnson (NYSE:JNJ)

Chase Investment Counsel Corp lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 64.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,313 shares of the company’s stock after selling 2,426 shares during the period. Chase Investment Counsel Corp’s holdings in Johnson & Johnson were worth $207,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Nicholas Hoffman & Company LLC. raised its holdings in shares of Johnson & Johnson by 0.7% during the 2nd quarter. Nicholas Hoffman & Company LLC. now owns 33,925 shares of the company’s stock valued at $4,958,000 after purchasing an additional 250 shares in the last quarter. Foster & Motley Inc. raised its holdings in shares of Johnson & Johnson by 2.8% during the 2nd quarter. Foster & Motley Inc. now owns 47,731 shares of the company’s stock valued at $6,976,000 after purchasing an additional 1,298 shares in the last quarter. Meridian Wealth Advisors LLC raised its holdings in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Meridian Wealth Advisors LLC now owns 14,468 shares of the company’s stock valued at $2,115,000 after purchasing an additional 234 shares in the last quarter. Impact Partnership Wealth LLC raised its holdings in shares of Johnson & Johnson by 428.1% during the 2nd quarter. Impact Partnership Wealth LLC now owns 7,034 shares of the company’s stock valued at $1,028,000 after purchasing an additional 5,702 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators raised its holdings in shares of Johnson & Johnson by 2.5% during the 2nd quarter. Deseret Mutual Benefit Administrators now owns 12,754 shares of the company’s stock valued at $1,864,000 after purchasing an additional 307 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of several recent analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 30th. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Tuesday. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Finally, TD Cowen dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $173.21.

Insider Activity

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. The transaction was disclosed in a document filed with the SEC, which is available through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $164.41 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The firm’s 50-day simple moving average is $157.57 and its 200-day simple moving average is $153.83. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The firm has a market cap of $395.68 billion, a P/E ratio of 10.25, a price-to-earnings-growth ratio of 2.73 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same period in the previous year, the business earned $2.80 EPS. The firm’s revenue was up 4.3% on a year-over-year basis. As a group, research analysts expect that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.